{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:35:56Z","timestamp":1785533756332,"version":"3.56.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Medical Scientist Training Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis and Crohn disease (CD) are epidemiologically associated with each other. The contribution of genetics and modifiable lifestyle factors to the development of comorbid disease is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the associations between polygenic risk score (PRS) and modifiable lifestyle factors and the development of comorbid psoriasis and CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective cohort study utilizing PRS and survey data on modifiable lifestyle factors. We examined their associations with the development of comorbid psoriasis and CD in patients of European ancestry in the UK Biobank. Kaplan\u2013Meier survival analysis and multivariable Cox proportional hazards regression models were used to evaluate the association between the studied variables and the risk of comorbid disease development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 430 758 participants, with 124 cases (comorbid psoriasis and CD) and 430 634 controls. A significant difference (P &amp;lt; 0.001; log-rank test) in disease-free survival time was observed across the four genetic risk groups (higher vs. lower risk). In the multivariable Cox proportional hazards regression analysis, the PsO-Hi and CD-Hi groups demonstrated a higher hazard ratio than the PsO-Lo and CD-Lo genetic reference group (hazard ratio 8.34, 95% confidence interval 4.17\u201316.7; P &amp;lt; 0.001). This trend was also observed in both the group with psoriasis onset first and the group with CD onset first.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that the development of comorbid psoriasis and CD is significantly associated with a higher genetic risk of both conditions, a trend that was consistent regardless of the disease of first onset. Future studies should validate these findings in an independent cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf285","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:38:00Z","timestamp":1751355480000},"page":"2232-2239","source":"Crossref","is-referenced-by-count":2,"title":["Associations of genetic risk and modifiable lifestyle factors with comorbid psoriasis and Crohns disease"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-5686","authenticated-orcid":false,"given":"Vikram R","family":"Shaw","sequence":"first","affiliation":[{"name":"Institute for Clinical and Translational Research, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of New Mexico Health Science Center , Albuquerque, NM ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of New Mexico Health Science Center , Albuquerque, NM ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-0548","authenticated-orcid":false,"given":"Jeffrey M","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher I","family":"Amos","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Translational Research, Baylor College of Medicine , Houston, TX ,","place":["USA"]},{"name":"Department of Internal Medicine, University of New Mexico Health Science Center , Albuquerque, NM ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025102707122850200_llaf285-B1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2025102707122850200_llaf285-B2","first-page":"e82","article-title":"Psoriasis associated with inflammatory bowel disease: a cross-sectional analysis in the NIH All of Us Research Program","volume":"63","author":"Joel","year":"2024","journal-title":"Int J Dermatol"},{"key":"2025102707122850200_llaf285-B3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025102707122850200_llaf285-B4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025102707122850200_llaf285-B5","first-page":"257","article-title":"Is psoriasis treatment a risk factor for inflammatory bowel disease?","volume":"34","author":"Nehring","year":"2020","journal-title":"Pharmaceut Med"},{"key":"2025102707122850200_llaf285-B6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat Genet"},{"key":"2025102707122850200_llaf285-B7","doi-asserted-by":"crossref","first-page":"2281658","DOI":"10.1080\/07853890.2023.2281658","article-title":"Integrated analysis of Mendelian randomization and Bayesian colocalization reveals bidirectional causal association between inflammatory bowel disease and psoriasis","volume":"55","author":"Cai","year":"2023","journal-title":"Ann Med"},{"key":"2025102707122850200_llaf285-B8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jaad.2014.06.043","article-title":"Modifiable lifestyle factors in psoriasis: screening and counseling practices among dermatologists and dermatology residents in academic institutions","volume":"71","author":"Adler","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025102707122850200_llaf285-B9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025102707122850200_llaf285-B10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.14309\/ajg.0000000000002180","article-title":"The contribution of genetic risk and lifestyle factors in the development of adult-onset inflammatory bowel disease: a prospective cohort study","volume":"118","author":"Sun","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025102707122850200_llaf285-B11","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLOS Med"},{"key":"2025102707122850200_llaf285-B12","doi-asserted-by":"publisher","author":"Thompson","DOI":"10.1101\/2022.06.16.22276246"},{"key":"2025102707122850200_llaf285-B13","doi-asserted-by":"crossref","first-page":"983902","DOI":"10.1155\/2013\/983902","article-title":"Correlations between psoriasis and inflammatory bowel diseases","volume":"2013","author":"Skroza","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025102707122850200_llaf285-B14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am J Hum Genet"},{"key":"2025102707122850200_llaf285-B15","doi-asserted-by":"crossref","first-page":"15037","DOI":"10.3748\/wjg.v20.i41.15037","article-title":"Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region","volume":"20","author":"Muro","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025102707122850200_llaf285-B16","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/art.21393","article-title":"Evidence for common genetic control in pathways of inflammation for Crohn\u2019s disease and psoriatic arthritis","volume":"52","author":"Ho","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025102707122850200_llaf285-B17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"2025102707122850200_llaf285-B18","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/13543784.2013.806483","article-title":"IL-17 targeted therapies for psoriasis","volume":"22","author":"Chiricozzi","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"2025102707122850200_llaf285-B19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025102707122850200_llaf285-B20","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"2025102707122850200_llaf285-B21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102707122850200_llaf285-B22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2025102707122850200_llaf285-B23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2025102707122850200_llaf285-B24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"2025102707122850200_llaf285-B25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"2025102707122850200_llaf285-B26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for psoriasis","volume":"42","author":"Wride","year":"2024","journal-title":"Dermatol Clin"},{"key":"2025102707122850200_llaf285-B27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jaad.2022.04.006","article-title":"Associations of combined lifestyle and genetic risks with incident psoriasis: a prospective cohort study among UK Biobank participants of European ancestry","volume":"87","author":"Shen","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025102707122850200_llaf285-B28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/nu15040840","article-title":"The impact of diet and physical activity on psoriasis: a narrative review of the current evidence","volume":"15","author":"Duchnik","year":"2023","journal-title":"Nutrients"},{"key":"2025102707122850200_llaf285-B29","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.3390\/nu12123751","article-title":"Diet advice for Crohn\u2019s disease: FODMAP and beyond","volume":"12","author":"Popa","year":"2020","journal-title":"Nutrients"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf285\/63638090\/llaf285.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2232\/63638090\/llaf285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2232\/63638090\/llaf285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:12:36Z","timestamp":1761563556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/11\/2232\/8180600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf285","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,1]]}}}